• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆载脂蛋白 E 升高与非酒精性脂肪性肝病相关:PREVEND 研究。

Plasma ApoE elevations are associated with NAFLD: The PREVEND Study.

机构信息

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

PLoS One. 2019 Aug 6;14(8):e0220659. doi: 10.1371/journal.pone.0220659. eCollection 2019.

DOI:10.1371/journal.pone.0220659
PMID:31386691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6684074/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is featured by increased plasma very low density lipoproteins (VLDL). The extent to which plasma apolipoprotein E (ApoE) levels are elevated in NAFLD is unclear. We determined whether plasma ApoE is elevated in subjects with suspected NAFLD. Plasma ApoE and genotypes were determined in 6,762 participants of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort. A Fatty Liver Index (FLI) ≥ 60 was used as a proxy of NAFLD. A total of 1,834 participants had a FLI ≥ 60, which coincided with increased triglycerides, non-HDL cholesterol, ApoB and ApoE (all P<0.001). In multivariable linear regression analysis, plasma ApoE levels were positively associated with an elevated FLI when taking account of ApoE genotypes and other clinical and laboratory covariates (fully adjusted model: β = 0.201, P<0.001). Stratified analysis for ApoE genotypes (ApoE ε3ε3 homozygotes, ApoE ε2 carriers, and ApoE ε3ε4 and ε4ε4 carriers combined), also showed positive associations of plasma ApoE levels with an elevated FLI in each group (all P<0.001). In conclusion, it is suggested that NAFLD is characterized by increased plasma ApoE levels, even when taking account of the various ApoE genotypes. Increased plasma ApoE may contribute to altered VLDL metabolism and to increased atherosclerosis susceptibility in NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)的特征是血浆极低密度脂蛋白(VLDL)增加。NAFLD 患者血浆载脂蛋白 E(ApoE)水平升高的程度尚不清楚。我们旨在确定疑似 NAFLD 患者的血浆 ApoE 是否升高。在预防肾脏和血管终末期疾病(PREVEND)队列的 6762 名参与者中,确定了血浆 ApoE 和基因型。脂肪性肝病指数(FLI)≥60 用作 NAFLD 的替代指标。共有 1834 名参与者的 FLI≥60,这与甘油三酯、非高密度脂蛋白胆固醇、ApoB 和 ApoE 升高一致(均 P<0.001)。在多变量线性回归分析中,当考虑 ApoE 基因型和其他临床及实验室协变量时,血浆 ApoE 水平与升高的 FLI 呈正相关(完全调整模型:β=0.201,P<0.001)。对 ApoE 基因型(ApoE ε3ε3 纯合子、ApoE ε2 携带者和 ApoE ε3ε4 和 ε4ε4 携带者合并)进行分层分析,也显示了血浆 ApoE 水平与每个组中升高的 FLI 之间的正相关关系(均 P<0.001)。总之,提示 NAFLD 的特征是血浆 ApoE 水平升高,即使考虑到各种 ApoE 基因型也是如此。增加的血浆 ApoE 可能导致 VLDL 代谢改变,并增加 NAFLD 中的动脉粥样硬化易感性。

相似文献

1
Plasma ApoE elevations are associated with NAFLD: The PREVEND Study.血浆载脂蛋白 E 升高与非酒精性脂肪性肝病相关:PREVEND 研究。
PLoS One. 2019 Aug 6;14(8):e0220659. doi: 10.1371/journal.pone.0220659. eCollection 2019.
2
Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.胆固醇外排能力在脂肪性肝指数升高的受试者中受损,脂肪性肝指数是一种非酒精性脂肪肝的替代指标。
Atherosclerosis. 2018 Oct;277:21-27. doi: 10.1016/j.atherosclerosis.2018.07.028. Epub 2018 Jul 27.
3
High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.非酒精性脂肪性肝病中载脂蛋白B血脂异常的高患病率:生命线队列研究
Metabolism. 2017 Jul;72:37-46. doi: 10.1016/j.metabol.2017.04.004. Epub 2017 Apr 13.
4
Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids.非酒精性脂肪性肝病与 2 型糖尿病发病风险:循环支链氨基酸的作用。
Nutrients. 2019 Mar 26;11(3):705. doi: 10.3390/nu11030705.
5
Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.非酒精性脂肪性肝病无创评分与核磁共振脂蛋白异常之间的关系:聚焦致动脉粥样硬化性血脂异常
J Clin Lipidol. 2017 Mar-Apr;11(2):551-561.e7. doi: 10.1016/j.jacl.2017.02.001. Epub 2017 Feb 22.
6
Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study.在预防终末期肾病和血管疾病研究中,载脂蛋白E水平和载脂蛋白E基因型与新发心血管疾病风险的关系
J Clin Lipidol. 2016 Jul-Aug;10(4):842-850. doi: 10.1016/j.jacl.2016.03.003. Epub 2016 Mar 12.
7
Effects of the ApoE polymorphism on plasma lipoproteins in Mexican Americans.载脂蛋白E基因多态性对墨西哥裔美国人血浆脂蛋白的影响。
Ann Epidemiol. 2000 Nov;10(8):524-31. doi: 10.1016/s1047-2797(00)00074-0.
8
Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease.血浆卵磷脂:胆固醇酰基转移酶和磷脂转移蛋白活性与非酒精性脂肪性肝病独立相关。
Eur J Clin Invest. 2018 Sep;48(9):e12988. doi: 10.1111/eci.12988. Epub 2018 Jul 13.
9
Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.尽管非酒精性脂肪性肝病患者的高密度脂蛋白胆固醇水平较低,但血清对氧磷酶 1 活性却保持不变。
J Lipid Res. 2019 Jan;60(1):168-175. doi: 10.1194/jlr.P088997. Epub 2018 Nov 19.
10
Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study.抗载脂蛋白A1抗体、非酒精性脂肪性肝病与心血管风险:一项转化研究。
J Transl Med. 2023 Oct 5;21(1):694. doi: 10.1186/s12967-023-04569-7.

引用本文的文献

1
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC.单细胞转录组揭示了从MASH向HCC转变过程中免疫微环境的重编程。
Mol Cancer. 2025 Jun 11;24(1):177. doi: 10.1186/s12943-025-02370-2.
2
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.通过组学技术解析代谢功能障碍相关脂肪性肝病
Int J Mol Sci. 2025 Feb 13;26(4):1589. doi: 10.3390/ijms26041589.
3
Ancestral bisphenol A exposure led to non-alcoholic fatty liver disease and sex-specific alterations in proline and bile metabolism pathways in the liver.祖先暴露于双酚A会导致非酒精性脂肪性肝病以及肝脏中脯氨酸和胆汁代谢途径的性别特异性改变。
Environ Toxicol Chem. 2025 Apr 1;44(4):958-972. doi: 10.1093/etojnl/vgae081.
4
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction-Associated Steatotic Liver Disease.氧化载脂蛋白肽组可表征代谢功能障碍相关脂肪性肝病。
Liver Int. 2025 Feb;45(2):e16200. doi: 10.1111/liv.16200.
5
Causal relationship between non-alcoholic fatty liver disease and sarcopenia: a bidirectional Mendelian randomization study.非酒精性脂肪性肝病与肌肉减少症之间的因果关系:一项双向孟德尔随机化研究
Front Med (Lausanne). 2024 Sep 18;11:1422499. doi: 10.3389/fmed.2024.1422499. eCollection 2024.
6
Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content.全基因组研究揭示了肝内脂肪含量的遗传风险因素。
Genomics Proteomics Bioinformatics. 2024 Jul 3;22(2). doi: 10.1093/gpbjnl/qzae031.
7
Association between maternal blood lipids and neonatal hypoglycaemia in pregnancy with gestational diabetes mellitus: a cohort study.母亲血脂与妊娠合并糖尿病新生儿低血糖的关系:队列研究。
Lipids Health Dis. 2024 Jun 7;23(1):170. doi: 10.1186/s12944-024-02168-z.
8
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study.依帕列净和西他列汀对 2 型糖尿病患者血脂和载脂蛋白谱的影响存在差异:SUCRE 研究。
Cardiovasc Diabetol. 2024 Feb 8;23(1):56. doi: 10.1186/s12933-024-02149-7.
9
Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets.对代谢功能障碍相关脂肪性肝病的基因组和蛋白质组进行分析可确定潜在的治疗靶点。
medRxiv. 2023 Nov 30:2023.11.30.23299247. doi: 10.1101/2023.11.30.23299247.
10
Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics.与脂肪性肝病相关的基因变异:诊断与治疗的机遇
Biomedicines. 2023 Oct 17;11(10):2809. doi: 10.3390/biomedicines11102809.

本文引用的文献

1
Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.尽管非酒精性脂肪性肝病患者的高密度脂蛋白胆固醇水平较低,但血清对氧磷酶 1 活性却保持不变。
J Lipid Res. 2019 Jan;60(1):168-175. doi: 10.1194/jlr.P088997. Epub 2018 Nov 19.
2
Serum paraoxonase-1 activity is associated with light to moderate alcohol consumption: the PREVEND cohort study.血清对氧磷酶-1 活性与轻至中度饮酒有关:PREVEND 队列研究。
Am J Clin Nutr. 2018 Dec 1;108(6):1283-1290. doi: 10.1093/ajcn/nqy217.
3
Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer?肝脂肪变性:第三个千年的新流行病。良性肝脏状态还是沉默杀手?
Eur J Intern Med. 2017 Dec;46:1-5. doi: 10.1016/j.ejim.2017.06.024. Epub 2017 Jul 6.
4
Non-alcoholic fatty liver disease: An expanded review.非酒精性脂肪性肝病:扩展综述
World J Hepatol. 2017 Jun 8;9(16):715-732. doi: 10.4254/wjh.v9.i16.715.
5
High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.非酒精性脂肪性肝病中载脂蛋白B血脂异常的高患病率:生命线队列研究
Metabolism. 2017 Jul;72:37-46. doi: 10.1016/j.metabol.2017.04.004. Epub 2017 Apr 13.
6
Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort.《生命线研究中非酒精性脂肪性肝病的患病率及影响因素:一项大型荷兰人群队列研究》
PLoS One. 2017 Feb 2;12(2):e0171502. doi: 10.1371/journal.pone.0171502. eCollection 2017.
7
Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age.脂肪肝和肝脂肪变性指数与心血管疾病风险的关联:与年龄的相互关系。
Clin Chim Acta. 2017 Mar;466:54-60. doi: 10.1016/j.cca.2017.01.008. Epub 2017 Jan 10.
8
Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study.在预防终末期肾病和血管疾病研究中,载脂蛋白E水平和载脂蛋白E基因型与新发心血管疾病风险的关系
J Clin Lipidol. 2016 Jul-Aug;10(4):842-850. doi: 10.1016/j.jacl.2016.03.003. Epub 2016 Mar 12.
9
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
Diabetologia. 2016 Jun;59(6):1121-40. doi: 10.1007/s00125-016-3902-y.
10
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中极低密度脂蛋白的特征可预测脂肪性肝炎和肝纤维化。
Liver Int. 2016 Aug;36(8):1213-20. doi: 10.1111/liv.13076. Epub 2016 Feb 24.